Immunic, Inc. (NASDAQ:IMUX – Get Rating) CEO Daniel Vitt purchased 8,000 shares of the firm’s stock in a transaction on Tuesday, November 22nd. The shares were acquired at an average cost of $1.35 per share, for a total transaction of $10,800.00. Following the completion of the purchase, the chief executive officer now directly owns 376,877 shares of the company’s stock, valued at approximately $508,783.95. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Immunic Stock Performance
Shares of NASDAQ:IMUX traded up $0.05 during midday trading on Thursday, hitting $1.36. 1,089,820 shares of the stock traded hands, compared to its average volume of 2,007,950. The business’s 50 day moving average is $3.67 and its two-hundred day moving average is $4.19. Immunic, Inc. has a one year low of $1.31 and a one year high of $14.50.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the business. Parkman Healthcare Partners LLC lifted its holdings in Immunic by 11.8% in the 1st quarter. Parkman Healthcare Partners LLC now owns 1,089,251 shares of the company’s stock worth $12,309,000 after buying an additional 115,068 shares during the period. RTW Investments LP lifted its stake in Immunic by 57.7% in the first quarter. RTW Investments LP now owns 2,705,513 shares of the company’s stock worth $30,572,000 after acquiring an additional 990,043 shares during the period. DLD Asset Management LP purchased a new stake in Immunic in the first quarter worth $565,000. Jacobs Levy Equity Management Inc. bought a new stake in Immunic in the third quarter valued at $80,000. Finally, Marshall Wace LLP purchased a new position in Immunic during the 3rd quarter valued at $77,000. Hedge funds and other institutional investors own 59.77% of the company’s stock.
Analysts Set New Price Targets
Immunic Company Profile
Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.
- Get a free copy of the StockNews.com research report on Immunic (IMUX)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.